Krakow, Poland – 13 September 2018 – Selvita will present and exhibit at the upcoming Medicinal Chemistry Summit: USA, which will be held on 17–18 September 2018 at the Hyatt Regency, Boston Harbour (MA, USA).
The Summit is designed for those working across all areas of medicinal chemistry. The international conference has three tracks focusing on key issues such as optimizing hit to lead quality and timescale, protein degradation, DNA encoded libraries, small molecule immuno-oncology research, SBDD, and the use of AI in the drug discovery process. This event will gather representatives of leading pharmaceutical and biotech companies worldwide.
The presentation will be held by Dr. Anna Karawajczyk, Team Leader of Computational Chemistry, who will talk about: “Computational OR medicinal chemistry – are they real alternatives? Selvita’s approach to a PDE4 inhibitor program.”
The presentation will take place on Monday, September 17, 2:20pm.
Throughout the whole event, you can visit Selvita’s team at booth #8.
To contact Selvita’s delegates at this conference, please contact us at: firstname.lastname@example.org, or +1 617 858 9732.
Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the USA (Greater Boston, San Francisco Bay), and in the UK (Cambridge). Selvita has currently several projects at early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).
+48 660 797 362